Yesterday, Monday, December 11, British pharmaceutical company Glasgow Smith Kline announced that it has finally obtained European approval to sell “Jemperli”, a drug used to treat women with endometrial cancer and is given in conjunction with chemotherapy.
This decision came based on a study that showed a positive effect of the treatment in terms of “progression-free survival” of cancer, the period during which the patient’s cancer does not worsen, and overall survival.
In their statement, the company indicated that the European Commission has approved the sale of “Jemperli” (the trade name for Dostarlimab), which is taken with carboplatin and paclitaxel (chemotherapy) to women with advanced endometrial cancer if it was newly discovered or recurrent.
Endometrial cancer usually affects women after menopause and initially appears in the layer of cells that form the inner lining of the uterus. It is considered one of the most common types of cancer among women, with the number of cases reaching about ten thousand annually in France.
Although the hope of treatment is relatively better compared to other gynecological cancers, such as the cervix and ovary, it remains a cause of a large number of deaths.
It is worth noting that health authorities in other countries, including the United States, had previously approved the sale of the drug at the end of last summer.
